Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
